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Abstract
Purpose Historically, invasion of the inferior vena cava (IVC) represented advanced and often unresectable hepatic disease.With
surgical and anesthetic innovations, IVC resection and reconstruction have become feasible in selected patients. This review
assesses technical variations in reconstructive techniques and post-operative management.
Methods A comprehensive literature search was performed according to PRISMA. Inclusion criteria were (i) peer-reviewed
articles in English; (ii) at least three cases; (iii) hepatic IVC resection and reconstruction (January 2015–March 2020). Primary
outcomes were reconstructive technique, anti-thrombotic regimen, post-operative IVC patency, and infection. Secondary out-
comes included post-operative complications and malignant disease survival.
Results Fourteen articles were included allowing for investigation of 351 individual patients. Analysis demonstrated significant
heterogeneity in surgical reconstructive technique, anti-thrombotic management, and post-operative monitoring of patency. There
was increased utilization of ex vivo approaches and decreased use of venovenous bypass compared with previously published reviews.
Conclusion This review of literature published between 2015 and 2020 reveals persistent heterogeneity of hepatic IVC recon-
structive techniques and peri-operative management. Increased utilization of ex vivo approaches and decreased use of
venovenous bypass point towards improved operative techniques, peri-operative management, and anesthesia. In order to gain
evidence for consensus on management, a registry would be beneficial.
Keywords IVC resection . Reconstruction . Hepatic disease .Malignancy . Patency . Systematic review
Introduction
Historically, involvement of the inferior vena cava (IVC) by
hepatic tumor represented advanced, unresectable disease.
With venous invasion being relatively uncommon, the true
incidence has yet to be described; however, it is clearly asso-
ciated with a poor prognosis [1]. Further, there is typically a
poor response to chemotherapy or medical treatment, such
that surgery often offers the only option for improved survival
[2, 3]. Thus, beginning in the 1990s and the piggybacking off
techniques used with leiomyosarcoma, case reports and series
began to emerge demonstrating feasibility of IVC resection
and reconstruction in select populations [4–11]. These devel-
opments continued to evolve with convergence of transplant
techniques such as venovenous bypass, and total hepatic vas-
cular exclusion, together with portal vein embolization and
cardiopulmonary bypass [12, 13]. Further innovations such
as ex vivo resections and advances in chemotherapy expanded
the pool of potential surgical candidates [14]. Even with tech-
nical advances, associated surgical risk remains relatively high
and long-term survival is often poor [11].
There continues to be a lack of literature on clinical out-
comes of caval reconstructive replacement with the majority
of published reports being single-cases or small case series. As
such, the type of IVC reconstructive technique widely varies
among surgeons and centers [15]. Typically, it depends on
tumor location, adherence, and circumferential venous
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involvement. Reconstructive options include primary repair,
graft replacement, patch replacement, and if adequate collat-
eral circulation is present may even permit ligation [10]. Once
modality of repair is decided, controversy still exists over
conduit material with an amalgam available including autolo-
gous vein, cadaveric donor allograft, and various synthetics.
The most widely used prosthesis tends to be the readily avail-
able ringed PTFE graft due to strength and size variety
allowing for diameter congruency [8, 10, 16]. Recently, car-
diothoracic data suggests venous biological grafts may be su-
perior to PTFE due to improved long-term patency and de-
creased infection risk although this data is not specific on IVC
reconstruction [17, 18]. In transplant programs, a preferred
material has been the use of preserved organ donor iliac veins
which unfortunately is not allowed in the USA under current
United Network for Organ Sharing (UNOS) guidance outside
of the transplant setting [19–21].
There is a paucity of data assessing post-operative mor-
bidity by type and material of IVC reconstruction and no
general consensus on use and duration of anti-thrombotic
therapy. While good long-term patency has been demon-
strated without intraoperative or post-operative anti-
thrombotics due to high IVC flow rates, others report
the necessity of long-term therapy with synthetic graft
repair [1, 3, 16, 22–24]. Moreover, many studies lack
descriptions of post-operative patency monitoring proto-
cols or only obtain imaging if clinical concern [16].
Infection, although rare, is another concern, particularly
with synthetic grafts with some surgeons advocating
omental interposition techniques [4, 5, 24, 25]. Long-
term outcomes vary with data on retroperitoneal tumors
suggesting a survival difference between IVC primary or
patch repair with circumferential resection [16].
There have been two recent comprehensive reviews
evaluating articles up to 2015 and to 2016, assessing
the safety and efficacy of IVC reconstruction during
hepatic resection [26, 27]. These demonstrate a wide
variety in technique and management including use of
anti-thrombotic guidelines and routine assessment of
post-operative patency. With IVC resection continuing
to be more frequently performed, we sought to conduct
a systematic review of articles published between 2015
and 2020. Our aim was to assess current trends and
evaluate the efficacy of technical variations in recon-
structive techniques as well as post-operative manage-
ment strategies to reduce morbidity, mortality, and im-
prove long-term survival.
Methods
A comprehensive literature search was performed by two in-
dependent researchers (MBG, DV) according to PRISMA
guidelines using PubMed, Medline, and EMBASE databases
in March of 2020 to investigate variance and outcomes by
IVC reconstruction techniques (Fig. 1) [28]. The databases
were searched with the Medical Subject Headings and key-
words outlined in Table 4 in Appendix 1. Titles were screened
and abstracts were reviewed for relevance. Relevant abstracts
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were (i) peer-reviewed articles in English; (ii) at least three
patient cases described; (iii) studies including hepatic IVC
resection and reconstruction published between January 01,
2015, and March 10, 2020. Case reports were excluded as
were cases of IVC resection without concurrent hepatec-
tomy. Studies that included cases not meeting criteria
for the systemic review were not included if the out-
comes were not separated and differentiated from the
outcomes of cases with IVC resections.
Two reviewers independently identified and extracted
data from the studies included in this systematic review
in which they were blinded to each other’s process.
Data abstraction included study characteristics (author,
year of publication etc.), patient demographics and dis-
ease characteristics, operative details, and outcomes
measured. The primary outcomes were IVC reconstruc-
tive technique, anti-thrombotic regimen, and post-
operative venous patency and infection. Secondary out-
comes included post-operative complications and surviv-
al (1-, 3-, and 5- year survival).
The methodological quality for the included trials was
assessed independently by two reviewers based on the
Newcastle-Ottawa scale [29]. Due to the significant heteroge-
neity observed among studies in terms of patient characteris-
tics and surgical details, meta-analysis was not performed.
Results
Literature review
The results of the search conducted in accordance with
PRSIMA guidelines are presented in Fig. 1. The initial
search resulted in 232 eligible articles. All of these titles
and abstracts were screened for relevance. Reasons for
exclusion included transplantation cases, pediatric patients
or resections without hepatic involvement. There were 76
articles that subsequently underwent full text review and
detailed evaluation. Of these, 62 articles were excluded
with the majority being either case reports, case series
with less than three cases, or review articles. Three arti-
cles were excluded as the outcomes from the venous re-
section group were not differentiated from the other pop-
ulations [30–32]. One article was omitted due to duplicate
data [33]. This resulted in 14 articles included in the final
qualitative synthesis [14, 34–46]. All 14 articles were case
series and thus uncontrolled-observational trials. The risk
of bias assessment with the Newcastle-Ottawa Scale was
assessed by two reviewers [29]. As all studies had no
control groups, they were scored four points out of seven
which is considered to be of poor quality due to missing
control.
Study population and surgical characteristics
Patient demographics and primary disease processes are
outlined in Table 1 and Table 5 Appendix 2. Several studies
presented stratified data by diagnosis or operative technique
and are represented accordingly in the tables [36, 41, 44, 46].
Of the 14-case series examined, there were 351 patients stud-
ied with ages ranging between 30 and 72 years of whom 34%
were female. The most common hepatic diseases were hepa-
tocellular carcinoma (HCC) (54%) and hepatic alveolar echi-
nococcosis (HAE) (29%). Remaining diagnoses included
intrahepatic cholangiocarcinoma (IHCC) (3%), colorectal liv-
er metastases (CLM) (4%), adrenal carcinoma (1.4%),
leiomyosarcoma (< 1%), and other diseases (1.4%).
Surgical resection approach and technique varied with report-
ed data outlined in Table 1. Techniques involving resection under
hypothermic perfusion include ante situm, in vivo, and ex vivo
approaches. Cross-clamping of themajor vessels with division of
the suprahepatic IVC alone, conserving the hepatic artery and
portal pedicle, describes the ante situm technique [47]. Similarly,
in situ exposure cross-clamps the major vessels but does not
transect the IVC. Lastly, the ex vivo approach divides all major
vessels to allow for entire liver removal with resection on the
backbench followed by autotransplantation [48]. Unfortunately,
these procedures are limited by hepatic intolerance to warm is-
chemia, hemodynamic instability, and intestinal vasculature con-
gestion [49]. In an attempt to ameliorate these complications,
venovenous bypass and hypothermic hepatic perfusion are com-
monly used strategies [31, 43, 50]. Of the surveyed reports in this
review, 20% of cases utilized an ex vivo approach; whereas only
3% performed an ante situm resection and 10% an in situ ap-
proach. Venovenous bypass was used to preserve hemodynamic
stability in less than 2% of cases. Hepatic vein reimplantation
was required in almost a quarter of patients and operative time
and estimated blood loss varied quite extensively due to the
significant heterogeneity between procedures and populations.
IVC resection and reconstruction
IVC resection techniques varied between articles with details
only described for 203 of 350 patients. About one-third of
patients (32%) underwent a primary caval repair [35, 36, 39,
41–43, 45]. Two studies described ligation without repair
which was only 7% of described cases [36, 44]. Forty percent
of patients had synthetic graft replacement, typically with
PTFE graft [14, 34, 35, 42, 43, 45, 46]. Autologous graft
replacement was another described technique using either
the saphenous vein or inferior mesenteric vein (IMV) for
17% of cases [36, 43]. Patch closure was only used in
3% of cases with either synthetic PTFE patches or an
autologous vein patch with the IMV [34, 36, 39, 41,
43]. Three studies did not provide any detail on IVC
resection and reconstruction [37, 38, 40].
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Anti-thrombotic regimen
The use and description of peri-operative and post-operative anti-
thrombotics were not provided in amajority of examined studies.
Three studies provided adequate detail: (1) prophylactic heparin
30 days post-operatively; (2) prophylactic low molecular weight
heparin (LMWH) from post-operative day two until discharge;
and (3) LMWH in hospital followed by coumadin at discharge
for 90 days (Table 6 in Appendix 3) [35, 36, 46].
Venous patency and infection
IVC patency was reported in 158 patients from nine of the 14
studies (Table 6 in Appendix 3). Venous occlusions were
identified in 2.5% of cases, resulting in a 97.5% patency rate.
Two studies found post-operative thromboses in the recon-
structed IVC [35, 46]. Two studies found outflow stenosis
with subsequent balloon dilatation for treatment [36, 42].
Only one study reported a reconstructed vessel infection; the
remaining studies did not note any infections [46].
Post-operative outcomes and long-term oncologic
survival
Table 6 inAppendix 3 demonstrates follow-up and survival with
all 14 studies reporting Clavien-Dindo major and minor compli-
cation rates [51]. Overall morbidity rate was 47.6% with the
highest grade of complication reported minor in 19.8%
(Clavien-Dindo < 3) and major in 27.5% (Clavien-Dindo ≥ 3).
There was a 30-day mortality rate of 3.1% (Table 2). Median
survival in patients with malignant disease ranged between 12
and 36 months with disease-free survival ranging between 4 and
30 months. One-year overall survival was 67.2% (50–85%), re-
ported in 245 patients. Three-year survival was 20.9% (0–34%),
reported in 217 patients, and 5-year survival was 22.7% (0–
30%), reported in 75 patients. Five-year survival was higher than
3-year survival as different studies were included due to varia-
tions in reporting overall survival.
Discussion
This systematic review of literature examined 14 recent case
series to evaluate technical approaches to IVC resection and
reconstruction. The outcomes of 351 diverse patients were
investigated and our assessment revealed a wide variety in
surgical practice, anti-thrombotic management, and post-
operative monitoring. As such, a consensus on best practice
remains to be elucidated.
Due to anatomic proximity, primary and secondary hepatic
tumors can invade the retrohepatic IVC, portending a poor
prognosis [1, 52]. Even with advances in chemotherapy, re-
section for such advanced tumors is the only potentially cura-
tive therapy, offering up to 50% 5-year survival [53–55].
Previously, this was a contraindication to resection; however,
considerable advancements made in conjunction with existing















Ko et al. [39] 8 14 (8–60) 0 (0) 71.0
Li et al. [46] 13 27.0 22.0 1 (7.7)* 84.6 23.1
Li et al. 23 16.0 13.0 3 (13)* 78.3 8.7
Li et al. 6 13.0 10.2 2 (33.3)* 83.3 0.0
Wen et al. [45] 15 21.6 (6–43) 1
Ho et al. [37] 4 12 (6–17) 8.5 (3–15) 0 (0) 50.0 0.0 0.0
Kasai et al. [38] 39 15.2 5.3 2 (5) 64.0 28.0 28.0
Vicente et al. [35] 4 36 (29–48) 29.5 (18–48)
Lee et al. [42] 3 16 (6–42) 4 (4–42) 0 (0) 66.0 33.0
Oldhafer et al. [43] 8 33.5 (0–107) 12 (0–107) 1 75.0 12.5
Baimas-George et al. [14] 3 12 (5–15) 12 (5–15) 12 (5–15) 0 (0)
Chen et al. [40] 105 14.0 8.7 2 64.2 19.7
Du et al. [44] 5 18.0 (17.0–35.0)
Du et al. 8 20.0 (13.5–33.0)
Shen et al. [36] 45 22 (6–66) 3*
Shen et al 28 22 (6–66) 3*
Tomimaru et al. [34] 12 42.7 (19–90) 0 (0) 66.7
Matsukuma et al. [41] 16 18.7 1* 61.0 34.0 17.0
Matsukuma et al. 8 12.6 0* 60.0 30.0 30.0
.OS overall survival. Values reported as No. (%), median (range), or average (± standard deviation)
*90-day mortality
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transplant surgical techniques have expanded technical op-
tions for vascular exclusion procedures and safe resection as
well as reconstruction [13, 14, 56–58]. As these procedural
constraints are overcome, the pool of eligible patients has
widened, making liver resection in patients with IVC involve-
ment increasingly common.
Depending on the extent of invasion, options for reconstruc-
tion vary and include primary repair, interposition graft, or patch
angioplasty (Fig. 2) [59]. Ligation of the IVC can be appropriate
if collateral circulation provides sufficient drainage and remains
intact [60]. Tumor location and circumferential involvement usu-
ally dictate resection approach [27]. Currently, limited data with
low grade of evidence is available on tumors requiring hepatec-
tomy with concomitant IVC resection and replacement in the
form mainly of case reports or small case series. As such, there
remains significant diversity present across and even within hos-
pital systems on best approach.
In this study, we combined individual patient data in an
attempt to elucidate a consensus on best practice for IVC
resection and reconstruction in hepatic disease. Upon review
and comprehensive analysis, that question remains unan-
swered because of the diverse population examined and the
majority of studies did not discuss rationale to approach and
conduit material preference. Synthetic graft replacement was
the most common method of repair followed by simple suture
repair. Autologous graft replacement was also relatively com-
mon with a variety of veins used as conduits. Post-operative
thrombotic treatment was described in adequate detail in only
three of the examined studies. Further, assessment and devel-
opment for post-operative obstruction by thrombosis or steno-
sis were only reported in half of the reviewed studies. Of these
158 patients, four patients developed obstruction, resulting in
an overall patency rate of 97.5%.
This systematic review assessed studies from the last half
decade: January 2015 throughMarch of 2020. In order to review
trends and shifts in approach,we compared these results with two
other comprehensive systematic reviews that assessed studies
between 2000 and 2015 and between 1980 and 2016 (Table 3)
[26, 27]. This demonstrated an upsurge in the total number of
cases per year involving vena caval reconstruction, revealing a
change in indication, particularly with more resections being
attempted for aggressive HCC and extensive resections for he-
patic alveolar echinococcosis (HAE) [61–64].
Variations in surgical technique demonstrate an increase in
e -vivo approaches: 20% versus only 5% and 4% in the past
two reviews. Thirteen percent of cases were performed via an
in situ or ante situm approach versus 0% and 4% in the prior
reviews, representing increasing dissemination of transplant
techniques to hepatobiliary surgery [14]. Additionally, use of
venovenous bypass was used in less than 2% of cases whereas
previously, it was in 20 to 30% of cases. These shifts in ap-
proach may demonstrate a trend away from routine use of
venovenous bypass with advancements in operative tech-
niques, anesthesia, and peri-operative patient managment
[65, 66]. Increasing knowledge of physiology has eliminated
it as the only option for augmenting preload, replaced by zeal-
ous use of vasopressors and volume, with the only true limit-
ing factor requiring venovenous bypass being intestinal ische-
mia. Additionally, high complication rates as well as increased
operative times and warm ischemia are associated with
venovenous bypass; and the need for systemic heparinization,
particularly in patients with liver disease and coagulation ab-
normalities, can have negative effects [67–71]. The concept of
hypothermic perfusion without venovenous bypass and devel-
opment of techniques to preserve caval flow have gained
Fig. 2 Anatomical drawings of IVC reconstruction: a primary repair; b
synthetic graft replacement; c patch closure
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momentum and demonstrate operative and/or post-operative
advantage or equivalence [43, 72–75].
Methods for IVC reconstruction appear to remain stable
over time with primary use of synthetic graft replacement or
suture repair. In general, tumor location and circumferential
involvement direct resection technique. Tangential resection
with a primary simple suture repair can be used if tumor in-
volves less than 25% of the vein circumference [76]. For tu-
mor adherence between 25 and 75% of wall circumference,
depending on location, partial resection with either suture re-
pair or patch may be utilized. Larger tumor involvement of
more than 75% vein circumference dictates the need for
segmental resection unless evidence of chronic infrarenal
IVC occlusion with adequate collateral formation is present.
Primary circumferential repair is preferred if the resection gap
is small enough such that the caval ends can be approximated
without tension, although most cases require a synthetic inter-
position graft with the preference of most surgeons being
PTFE. Our review demonstrates that an increase in ligation
without repair perhaps indicating an increasing willingness to
sacrifice the IVC, avoiding risk for pulmonary embolism.
Further, evolution of transplant techniques has led to hepatic
vein reconstruction likely resulting in the demonstrated in-
crease in autologous vein patching. Transplant literature also
Table 3 Comparisons between
comprehensive analyses of IVC
reconstruction systematic reviews
Baimas-George
et al. 2015 to 2020
Papamichail




N 351 238 258
Female (%) 119 (33.9) 100 (42) 133 (51.6)
Age 30–72 54 56.5 ± 12.3
Intrahepatic cholangiocarcinoma 10 (2.8) 62 (26) 51 (20)
Colorectal liver metastases 14 (4.0) 104 (43) 128 (50)
Hepatocellular carcinoma 191 (54.4) 45 (19) 48 (19)
Hepatic alveolar echinococcosis 101 (28.8) 0 (0) 0 (0)
Adrenal carcinoma 5 (1.4) 0 (0) 0 (0)
Leiomyosarcoma 2 (0.6) 10 (4) 0 (0)
Diagnosis: other 5 (1.4) 19 (7.9) 31 (11)
Surgical technique
Ex vivo approach 71 (20.2) 12 (5.0) 10 (4.0)
Ante situm approach 12 (3.4) 0 (0.0) 11 (4.0)
In situ approach 36 (10.3) 0 (0.0) 0 (0.0)
Venovenous bypass 6 (1.7) 43 (19.8) 69 (29.0)
Concomitant hepatic vein reconstruction 83 (23.6) 19 (9.3) 15 (6.0)
IVC reconstruction
Primary repair 65 (32.0) 86 (35.8) 115 (43.0)
Ligation without repair 15 (7.4) 0 (0.0) 3 (1.0)
Synthetic graft replacement 82 (40.4) 122 (50.8) 107 (42.0)
Autologous vein graft replacement 34 (16.7) 0 (0.0) 4 (2.0)
Homologous vein graft replacement 1 (0.5) 0 (0.0) 2 (1.0)
Synthetic patch closure 6 (3.0) 32 (13.3) 12 (5.0)
Autologous graft patch closure 0 (0.0) 0 (0.0) 8 (3.0)
Post-operative results
R0 resection rate 92 (84.4) 181 (84.8) –
Patency rate 154 (97.5) 116 (95.1) 258 (100.0)
Morbidity 167 (47.6) 74 (43.3) 101 (42.1)
30-day mortality 11 (3.1) 15 (6.25)* 14 (5.4)†
1-year OS 67.2% 78.1% 79%
3-year OS 20.9% 47.7% 45%
5-year OS 22.7% 40.0% 31%
.OS overall survival. Values reported as No. (%), median (range), or average (± standard deviation)
*In-hospital mortality
† Post-operative complication mortality
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demonstrates IVC reconstructive success using allograft iliac
vein from cadaveric donors which has started to infiltrate
hepatobiliary practice; however, this is not allowed in the
USA under current UNOS guidelines [19–21].
Post-operative patency rates remained high across all
three reviews at greater than 95%, morbidity rates have
remained stable at approximately 40%, and 30-day mor-
tality has decreased (Table 3). While difficult to draw
conclusions due to the population heterogeneity, this
may illustrate a progressive understanding of physiology
and technology. For, despite the fact that cases have
become increasingly complex, morbidity and acute mor-
tality have stayed the same. Conversely, there was a
decrease in survival. We hypothesize, particularly from
our own anecdotal experience, that this may be due to
more liberal criterion and a decrease in selection bias,
adopting an intention-to-treat approach inevitably
resulting in patients with worse prognoses getting oper-
ations. Additionally, the disease heterogeneity between
reviews demonstrates more operations for HCC in the
last half decade, which can affect survival rates.
This systematic review has many limitations. Due to the
rarity of the procedure, this is a selected group of patients
based on anatomy and disease biology factors who are candi-
dates for aggressive resection. Therefore, this data is clearly
susceptible to selection and recall bias. Further, this cohort of
patients has significant disease heterogeneity with HAE, an
aggressive form of hepatic hydatid disease, being included as
the primary focus was operative technique. Tumor involve-
ment with the IVC is dependent on disease type and, as such,
aggregate conclusions must be interpreted very cautiously. Of
note, only malignant disease cases were included in cumula-
tive survival estimates. Not every study examined had the
documented variables outlined in our results. For instance,
only 203 of 350 patients had IVC reconstructive tech-
nique described and in calculating overall survival, differ-
ent studies were included in each of the time periods due
to reporting variations, resulting in a higher 5-year than 3-
year survival rate. For this reason, tables with each
study’s individual results were included. This limited
our ability to conjecture on mortality and its relationship
to IVC replacement, post-operative complications such as
hepatic failure, or oncologic pathology. We did exclude
studies that did not have separate data for IVC resection
cases [30–32]. However, one study was included as it had
separate mortality outcomes for IVC resection although
did combine IVC resection with hepatic vein resection
for morbidity outcomes [40]. Since the majority of these
cases were for IVC resection (> 70%), these results were
included but must be interpreted cautiously. Finally, the
combination of search databases used to perform the sys-
tematic review is suboptimal as per the gold standard for
systematic reviews due to author access limitations [77].
This systematic review demonstrates a need for standard-
ized reporting of outcomes and establishment of an interna-
tional registry for appropriate, disease-based, best evidence
practice recommendations.
Conclusion
This systematic review examines the operative approach
and management of hepatic IVC resection and recon-
struction over the last half decade, with a witnessed
evolution in technique demonstrated. There was in-
creased utilization of ex vivo approaches and decreased
use of venovenous bypass compared with previously
published reviews which may indicate improvements in
operative techniques, peri-operative management, and
anesthesia. In order to gain evidence for a consensus
to be reached on operative and post-operative manage-
ment, a registry would be beneficial.
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Appendix 1
Table 4 Search terms combined using Boolean logic within column
terms combined using “or” statements; “and” statements used to
combine terms between columns
Inferior vena cava Surgery Hepatic Disease
Inferior vena cava Surgery Liver Malignancy
IVC Resection Hepatic Oncology
Vein Procedure Hepatobiliary Cancer
Venous Treatment Tumor
Surgical outcomes Disease
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Appendix 2
Table 5 Patient and disease characteristics
Study Year N Female (%) Age Tumor size (cm)
Ko et al. [39] 2016 8 2 (25) 72 (36–78) 7.5 (5.5–20.0)
Li et al. [46] 2016 13 23 6 5 (38.5) 6 (26.1) 1 (16.7) 50.1 ± 10.5 52.4 ± 11.2 51.7 ± 10.4
Wen et al. [45] 2016 15 8 (53.3) 38 (16–54)
Ho et al. [37] 2017 4 3 (75) 51.5 (38–72)
Kasai et al. [38] 2017 39 7 (17.9) 55 (49–67) 11.0 (7.0–13.0)
Vicente et al. [35] 2017 4 2 (50) 55 (43–63)
Lee et al. [42] 2018 3 3 (100) 51 (34–54)
Oldhafer et al. [43] 2018 8 6 (75) 55.5 (49–70)
Baimas-George et al. [14] 2019 3 3 (100) 41 (36–73) 11.3 (8.8–12.7)
Chen et al. [40] 2019 105 10 (9.5) 51 (48–57) 8.0 (5–11)
Du et al. [44] 2019 5 8 4 (80) 3 (37.5) 30.6 ± 8.3 37.1 ± 11.5 110.5 ± 43.0161.3 ± 57.1
Shen et al. [36] 2019 45 26 30 (66.7) 17 (60.7) 34.5 ( ± 9.9) 33.7 ( ± 10.5) 15.8 ± 2.612.0 ± 3.9
Tomimaru et al. [34] 2019 12 4 (33.3) 62 (39–79)
Matsukuma et al. [41] 2020 16 8 3 (18.8) 2 (25) 66 (60.5–75) 68 (63–73) 7.6 (5.4–12.5) 7.2 (6.3–13.1)
Values reported as No. (%), median (range), or average (± standard deviation)
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